New drug combo aims to stop Leukemia's return
NCT ID NCT05361057
Summary
This study tested whether combining the drugs venetoclax with azacytidine or DA could prevent relapse in acute myeloid leukemia (AML) patients who still had small amounts of cancer cells after initial treatment. The goal was to see if this 'preemptive' treatment could keep patients in remission longer. The trial was terminated early and enrolled only 20 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HBDH
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.